The WTO Does Not Protect Trade. It Protects Patents.

The Uruguay Round of trade negotiations concluded in 1994. It produced the World Trade Organization and, bundled inside the same package of agreements, something that had never before existed in international trade law: a binding global minimum standard for intellectual property protection. The Agreement on Trade-Related Aspects of Intellectual Property Rights — TRIPS — required all WTO member nations to adopt and enforce patent protections, copyright regimes, and trademark laws that met standards designed primarily by and for the intellectual property industries of the United States, Europe, and Japan.

The negotiation of TRIPS was not a multilateral process in any meaningful sense. It was driven by the Advisory Committee for Trade Policy and Negotiations, a private sector body populated by executives from Pfizer, IBM, Merck, Bristol-Myers Squibb, and other corporations whose business model depended on international IP enforcement. The USTR's chief negotiator on TRIPS was closely tied to the pharmaceutical industry. The final text reflected those interests with precision.

Developing nations, most of which had built domestic industrial capacity by not enforcing foreign patents — the same strategy the United States used in the 19th century to industrialize by ignoring European patents — were required to implement patent regimes that would prevent them from doing what rich nations had done to get rich.

The Pharmaceutical Chokehold

The most immediate and lethal consequence of TRIPS was in pharmaceuticals.

Before TRIPS, developing nations could manufacture generic versions of patented drugs. India's pharmaceutical industry had been built on this foundation: Indian companies produced generic versions of patented western drugs and sold them at a fraction of the branded price — to domestic consumers, to international aid organizations, and to other developing nations. Generic antiretrovirals for HIV/AIDS treatment cost approximately $300 per patient per year from Indian manufacturers. The branded equivalents from Pfizer and Glaxo cost $10,000-$15,000 per year.

When the AIDS epidemic devastated sub-Saharan Africa in the 1990s, the price differential was a death sentence. Governments in South Africa, Thailand, and Brazil attempted to exercise what TRIPS itself acknowledged as a theoretical right — compulsory licensing, allowing a government to override a patent in a public health emergency and license domestic production of a needed drug. The pharmaceutical industry's response was litigation, diplomatic pressure, and trade threats, coordinated through the US Trade Representative.

South Africa passed a Medicines Act in 1997 allowing compulsory licensing and parallel importation of generic drugs. Thirty-nine pharmaceutical companies sued the South African government. The Clinton administration — under pressure from the pharmaceutical lobby — threatened South Africa with trade sanctions. In 2001, faced with global public outrage and sustained pressure from MSF and other organizations, the pharmaceutical companies withdrew the lawsuit. But the attempt had been made, and the lesson had been delivered: attempt to undermine patent protection and the full weight of the US government and its allies will be brought to bear.

The Doha Declaration in 2001 reaffirmed that TRIPS should not prevent countries from accessing medicines for public health purposes. It was a political statement without enforcement mechanism. The pharmaceutical industry subsequently negotiated bilateral free trade agreements — with Jordan, Morocco, Chile, and others — that went further than TRIPS and explicitly restricted compulsory licensing rights that Doha had nominally protected.

Seeds and Agriculture

The TRIPS framework extends to agricultural biotechnology in ways that compound the consolidation dynamics of the seed industry.

TRIPS requires member nations to provide some form of protection for plant varieties — either through patents, a sui generis system, or both. In practice, this has been used by corporations like Bayer (Monsanto), Corteva, and Syngenta to extend patent protection over genetically modified seed varieties into markets where such protection did not previously exist.

The effect in practice: an Indian farmer using a seed variety that includes patented genetics — whether knowingly or not — is potentially liable for patent infringement under a legal regime the farmer had no role in creating and no democratic input into. The seed company that owns the patent operates under US or European law; the farmer operates under Indian or Brazilian law; TRIPS ensures those laws must ultimately align with the patent holder's interests.

The International Union for the Protection of New Varieties of Plants (UPOV) — a treaty organization closely aligned with the seed industry — has been used through trade agreement conditionality to push developing nations toward stronger plant variety protection systems. Nations that want trade agreements with the United States are expected to adopt UPOV 1991, which provides stronger corporate control over seed varieties and weaker farmer rights to save and replant seeds.

The TRIPS-Plus Ratchet

The pattern that emerged after TRIPS is what trade scholars call "TRIPS-Plus": the use of bilateral and regional free trade agreements to impose IP protections that go beyond TRIPS requirements, and to lock those protections in against future democratic revision.

The US-Jordan FTA, signed in 2000, required patent protection for pharmaceutical products that extended beyond what TRIPS required. The US-Chile FTA in 2003 included similar provisions. The Central America Free Trade Agreement (CAFTA) restricted compulsory licensing in ways that constrained public health responses. The Trans-Pacific Partnership — negotiated in secret with extensive pharmaceutical industry participation — would have extended patent terms, restricted generic drug entry, and imposed data exclusivity rules that would have delayed generic competition in markets across Asia and Latin America. (The TPP's IP chapter was leaked by WikiLeaks in 2013, revealing the extent of pharmaceutical industry drafting influence. The agreement ultimately failed to enter into force after US withdrawal, but its IP provisions have continued to appear in subsequent bilateral agreements.)

The TRIPS-Plus ratchet operates as a one-way mechanism: IP protections can be tightened through trade agreements, but they cannot be loosened. A country that signs a TRIPS-Plus FTA with the United States cannot subsequently revise its domestic IP law downward without triggering trade agreement violations and the threat of retaliatory tariffs.

Who Wrote the Rules

The structure of international IP law did not emerge from neutral negotiation. It was written, largely, by the industries that benefit from it.

Pfizer's CEO Edmund Pratt served on the USTR Advisory Committee that designed the TRIPS strategy. IBM's chairman John Opel co-chaired the advisory body. The Intellectual Property Committee — a lobbying coalition of Bristol-Myers, DuPont, General Electric, Hewlett-Packard, IBM, Johnson and Johnson, Merck, Monsanto, Pfizer, Rockwell, and Warner — produced a document in 1988 titled "Basic Framework of GATT Provisions on Intellectual Property" that became the template for TRIPS negotiations.

The developing nations that would be most affected by TRIPS were not at the table when it was being designed. They were presented with the final text and informed that WTO membership — essential for access to global trade — required acceptance.

This is the structure of "free trade." The rules are written by the parties with the most to gain from them. The parties with the most to lose are given no meaningful input. The institutions that enforce the rules are controlled by the rule-writers. And the ideology of free trade is used to legitimate the entire arrangement as neutral market economics rather than as what it is: the organized capture of global legal architecture by corporate interests.

The Enforcement Reality

When a developing nation attempts to step outside the TRIPS framework — through compulsory licensing, through domestic generic production, through policy that prioritizes public health over patent monopoly — the consequences are not abstract.

The USTR publishes an annual "Special 301 Report" identifying nations whose IP protection is deemed inadequate by the US pharmaceutical, software, and entertainment industries. Nations on the "Priority Watch List" face the prospect of trade sanctions, reduced market access, and exclusion from trade agreements. The list is explicitly curated based on submissions from industry associations. It is, functionally, a corporate complaint mechanism embedded in US trade policy.

India has been on the Special 301 Watch List for most of its existence as an independent pharmaceutical producing nation. India's patent law includes a provision — Section 3(d) — that prohibits the grant of patents for minor modifications of existing compounds unless the modification produces significantly enhanced efficacy. This provision was specifically designed to prevent "evergreening" — the pharmaceutical industry practice of filing new patents on trivially modified versions of existing drugs to extend monopoly protection beyond the original patent term. The US pharmaceutical industry has consistently lobbied for India to remove Section 3(d). India has refused. The trade pressure has been continuous.

The WTO does not protect trade. It protects the ability of corporations headquartered in wealthy nations to extract monopoly rents from the global economy. The developing nations that signed onto TRIPS in 1994 were told they were joining a system of rules-based international commerce. What they joined was a system that rules in favor of corporate IP, every time, against the health, agricultural, and industrial policy needs of their populations. That is not an accident. It is the design.